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Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) is an endogenous
neuropeptide with distinct functions including the regulation of inflammatory processes.
PACAP is able to modify the immune response by directly regulating macrophages
and monocytes inhibiting the production of inflammatory cytokines, chemokines and
free radicals. Here, we analyzed the effect of exogenous PACAP on peripheral immune
cell subsets upon acute infection with the parasite Toxoplasma gondii (T. gondii).
PACAP administration was followed by diminished innate immune cell recruitment to
the peritoneal cavity of T. gondii-infected mice. PACAP did not directly interfere with
parasite replication, instead, indirectly reduced parasite burden in mononuclear cell
populations by enhancing their phagocytic capacity. Although proinflammatory cytokine
levels were attenuated in the periphery upon PACAP treatment, interleukin (IL)-10 and
Transforming growth factor beta (TGF-β) remained stable. While PACAP modulated
VPAC1 and VPAC2 receptors in immune cells upon binding, it also increased their
expression of brain-derived neurotrophic factor (BDNF). In addition, the expression of p75
neurotrophin receptor (p75NTR) on Ly6Chi inflammatory monocytes was diminished upon
PACAP administration. Our findings highlight the immunomodulatory effect of PACAP
on peripheral immune cell subsets during acute Toxoplasmosis, providing new insights
about host-pathogen interaction and the effects of neuropeptides during inflammation.
Keywords: pituitary adenylate cyclase-activating polypeptide (PACAP), Toxoplasma gondii, acute infection,
monocytes, macrophages, innate immunity, neurotrophins
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INTRODUCTION
Pituitary adenylate cyclase-activating polypeptide (PACAP) is
a 38-amino-acid neuropeptide in the glucagon superfamily
together with secretin and vasoactive intestinal peptide (VIP)
(Sherwood et al., 2000). PACAP is widely expressed in the
peripheral and central nervous systems (CNS) and functions
as a neurotransmitter, neuromodulator and neurotrophic factor
(Waschek, 2002; Zhou et al., 2002; Dejda et al., 2005; Botia et al.,
2007; Armstrong et al., 2008; Abad and Tan, 2018). The nervous
and immune systems participate in a complex bidirectional cross-
talk through neuropeptides such as PACAP/VIP in multiple
organs (Abad and Tan, 2018). Correspondingly, PACAP strongly
improves the outcome of inflammatory disorders, such as
rheumatoid arthritis, septic shock, inflammatory bowel disease,
and multiple sclerosis in rodent models (Abad et al., 2001, 2003;
Martinez et al., 2002; Gonzalez-Rey et al., 2006; Tan et al., 2009).
PACAP acts by binding to three specific membrane receptors
from the G protein-coupled receptors (GPCR) family: PAC1,
VPAC1, and VPAC2. The PAC1 receptor is highly expressed in
the nervous system and possesses the highest affinity for PACAP,
while the receptors VPAC1 and VPAC2 have the same lower
affinity for PACAP, and are expressed among different cell types
(Pozo et al., 1997). The majority of immune cells express one
or more PACAP receptors. For example, PAC1 is expressed on
peritoneal macrophages, microglia and pulmonary dendritic cells
(DCs) (Delgado et al., 2004a). VPAC1 is constitutively expressed
in T cells, macrophages, monocytes and DCs (Delgado et al.,
2004a). VPAC2 is rarely expressed in these cells during a resting
state, but its expression is induced following lipopolysaccharide
(LPS) stimulation in vitro (Delgado et al., 1996b). Recently, the
expression of VPAC1 and VPAC2 was found in innate lymphoid
cells (ILC) 2 (Nussbaum et al., 2013), and has been implicated in
the resolution of inflammation (Talbot et al., 2015).
Many studies have demonstrated that PACAP acts as a
neuronal growth factor during development and regeneration
(Waschek, 2002; Deguil et al., 2007; Watanabe et al., 2007).
The neuromodulatory properties of PACAP were shown
to be involved with the neurotrophin signaling of brain-
derived neurotrophic factor (BDNF), promoting neuronal
survival and synaptic plasticity (Frechilla et al., 2001).
The family of neurotrophins is comprised of four secreted
proteins, characterized by their ability to modulate survival,
differentiation, and apoptosis of neurons (Bothwell, 2016).
BDNF, nerve growth factor (NGF), neurotrophin-3 (NT-3), and
neurotrophin-4 (NT-4) exert their functions via interaction with
tropomyosin receptor kinases (Trk) TrkA, TrkB, TrkC, and the
p75 neurotrophin receptor (p75NTR). The effect of PACAP on
neurotrophin signaling was presented in human monocytes,
where the exposure to the neuropeptide resulted in pro-
inflammatory cell activation with increased Ca2+ mobilization
(El Zein et al., 2006, 2007, 2008, 2010).
As an immunomodulator, PACAP exerts a dual role in
regulating innate immunity depending on the activation status
of cells and their environment. Several studies reported that
PACAP is a potent immunomediator for both innate and
adaptive immunity, primarily assuming an anti-inflammatory
role. Exposure to PACAP inhibits the pro-inflammatory response
of macrophages, such as the production of tumor necrosis
factor (TNF) (Delgado et al., 1999b) and interleukin 6 (IL-
6) (Martinez et al., 1998a), as well as the chemokines MCP-1
(CCL2), MIP1-α (CCL3) and RANTES (Delgado et al., 2003).
Additionally, PACAP treatment leads to polarization of T helper
cells to a Type 2 (Th2) phenotype (Delgado, 2003). It also
promotes the development of tolerogenic DCs and favors the
generation of regulatory T cells (Tregs), suppressors of immune
responses (Delgado et al., 2005). In contrast, PACAP was able
to stimulate the phagocytic activity, adhesion and mobility of
resting macrophages as well as release of free radicals and
IL-6 (Delgado et al., 1996a; Garrido et al., 1996; Martinez
et al., 1998b), associating PACAP with a crucial mechanism to
pathogen elimination.
Antiparasitic effects of PACAP were first described against
the protozoa Trypanosoma brucei, showing a membrane-
lytic effect, closely associated with autophagy and apoptosis-
like cell death (Delgado et al., 2009). More recently, we
showed that administration of PACAP ameliorated acute small
intestinal inflammation and extra-intestinal sequelae caused
by Toxoplasma gondii (T. gondii) infection (Heimesaat et al.,
2014; Bereswill et al., 2019). Toxoplasma gondii is an obligate
intracellular parasite acquired by oral ingestion of contaminated
food or water. The parasite infects the small intestine and
then differentiates to its rapidly replicating stage (tachyzoite),
which is able to infect all nucleated cells through active
penetration (Dobrowolski and Sibley, 1996). After crossing the
intestinal barrier, the parasites encounter both resident and
recruited immune cells, resulting in parasite elimination, antigen
presentation and cytokine production (Buzoni-Gatel et al., 2006).
The successful dissemination of T. gondii within the host
is highly dependent on invading migratory immune cells and
the ability of these immune cells to phagocyte the parasite.
Elimination of T. gondii involves a complex recruitment
of immunity-related GTPases (IRGs) and guanylate-binding
proteins (GBPs) (Zhao et al., 2009; Fentress et al., 2010). After
infection, these host defense factors are known to accumulate in
the membrane of the parasitophorous vacuole (PV) culminating
with its disruption and parasite elimination (Macmicking, 2012).
Moreover, a particular preference for myeloid cells has been
explored as a key mechanism for parasite dissemination into the
CNS (Weidner and Barragan, 2014; Blanchard et al., 2015).
Our group has previously demonstrated the critical
importance of myeloid cells controlling T. gondii infection
in the periphery as well as in the CNS (Dunay et al., 2008,
2010; Biswas et al., 2015; Mohle et al., 2016). Besides,
we recently showed the innate immune response and the
influence of neurotrophin signaling upon T. gondii-induced
neuroinflammation. Particularly, neurotrophin signaling via
p75NTR altered innate immune cell behavior and changed the
structural plasticity of neurons (Dusedau et al., 2019).
Here, we set out to evaluate the immunomodulatory effects
of PACAP on the innate immune response during T. gondii
acute infection. We show that PACAP is able to reduce
immune cell recruitment and enhance phagocytic capacity of
mononuclear cells, promoting parasite elimination. At the same
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time, the neuropeptide attenuated pro-inflammatory mediators
while upregulating its own receptors. Interestingly, we detected
altered expression of BDNF and p75NTR in peritoneal cells,
pointing toward the contribution of PACAP to the parasite
elimination and neurotrophin signaling in immune cells upon
acute Toxoplasmosis.
MATERIALS AND METHODS
Animals
Experiments were conducted with female C57BL/6JRj mice (8
weeks old, purchased from Janvier, Cedex, France). All animals
were group-housed in a 12 h day/night cycle at 22◦C with free
access to food andwater under specific-pathogen-free conditions,
according to institutional guidelines approved by the Animal
Studies Committee of Saxony-Anhalt.
T. gondii in vitro Culture
Tachyzoites of ME49 and PTG-GFP type II strain of T. gondii
were grown in monolayers of human foreskin fibroblast (HFF)
cells cultured inDMEMmedium (FG0435, Biochrom, Germany),
supplemented with 10% fetal bovine serum (FBS) (Thermo
Fisher, Germany), 1% Penicillin/Streptomycin (Pen/Strep; Sigma,
USA) and 1% non-essential amino acids (NEEA) (Thermo Fisher,
Germany) (Morisaki et al., 1995). HFF cells and tachyzoites were
scrapped from culture flasks, spinned down at 500× g for 10min
and passed through 20 and 22G needles to liberate intracellular
parasites. To obtain a host cell-free parasite suspension, the
solution was filtered through a 5µm Millex-SV syringe filter
(Millipore, Germany). The parasite suspension was pelleted at
800 × g for 20min, resuspended in 1ml sterile phosphate-
buffered saline (PBS) and the number of living tachyzoites was
determined by counting under a light microscope using Trypan
Blue 0.4%. Subsequently, the freshly egressed parasite suspension
was used for infections and plaque assay experiments.
Experimental Acute T. gondii Infection and
PACAP Administration
In order to investigate acute T. gondii infection in the peritoneal
cavity, all mice were infected by intraperitoneal (i.p.) injection
of 1 × 104 ME49 or PTG-GFP tachyzoites, freshly harvested
from HFF cultures, in a final volume of 200 µl with PBS. For
PACAP treatment, 50 µg (11 nmol/mouse) of the synthesized
neuropeptide PACAP38 dissolved in 200 µl of PBS was
administrated i.p. on days 2 and 4 post infection. Non-treated
control mice received PBS only. At day 5 post infection (dpi)
peritoneal exudate cells were collected by peritoneal lavage
(Fentress and Sibley, 2011) for further analysis. Spleens were
collected and stored in Allprotect Tissue Reagent (Qiagen,
Germany) at−80◦C until further processing.
Flow Cytometric Analysis
Single cell suspensions were first incubated with ZOMBIE NIRTM
fixable dye (BioLegend, San Diego, CA) or 7-AAD Viability
Staining Solution (BioLegend) for live/dead discrimination. To
prevent unspecific binding of antibodies, anti-FcγIII/II receptor
antibody (clone 93) was applied to cells before staining with
fluorochrome-conjugated antibodies against cell surface markers
in FACS buffer (PBS, supplemented with 2% FBS and 0.1%
sodium azide). CD11b (M1/70), Ly6C (HK1.4), MHCII I-
A/I-E (M5/114.15.2), and F4/80 (BM8) were all purchased
from eBioscience (San Diego, USA). Ly6G (1A8) and CD11c
(N418) were purchased from BioLegend and p75NTR (MLR2)
from Abcam (Germany). Cells were incubated for 30min at
4◦C, washed and subsequently analyzed. Fluorescence Minus
One (FMO) controls were used to determine the level of
autofluorescent signals for each conjugated antibody. Data was
acquired using a BD FACS Canto II (BD Biosciences, USA)
or Attune NxT flow cytometer (Thermo Fisher, Germany) and
analyzed using FlowJo (v10, FlowJo Inc., USA). A minimum of
2× 105 cells per samples were acquired.
Plaque Assay
All experiments were conducted using fresh syringe-released
extracellular tachyzoites. As previously described (Arroyo-Olarte
et al., 2015), 200 parasites per well were used to infect HFF
monolayers in six-well plates at different concentrations of
PACAP. Briefly, parasitized cells were incubated for 7 days, fixed
with cold methanol, and then stained with crystal violet. Plaques
were imaged and scored for their sizes and numbers using the
ImageJ software (NIH, US).
Generation of Bone Marrow-Derived
Macrophages
For generation of bone marrow-derived macrophages (BMDMs),
femurs and tibias of 8 to 12 weeks old C57BL/6JRj mice were
collected. Bones were flushed with a syringe filled with DMEM
(FG0435, Biochrom, Germany) containing 10% FBS and 1%
Pen/Strep to extrude bone marrow onto a 40µm cell strainer.
The obtained cell suspension was then spinned down for 10min
at 400 × g, 4◦C and the cells were seeded into 6 well/plate using
DMEM supplemented with 10% FBS, 1% Pen/Strep, 10 ng/ml
recombinant murine GM-CSF (315-03, PeproTech, USA) and
incubated at 37◦C, 5% CO2. After 10 days, cells were primed
to M1 macrophage phenotype with 150 Units/ml recombinant
murine IFN-γ (315-05, Peprotech, USA) for 10 h, and then with
20 ng/ml of LPS (L2630, Sigma-Aldrich, USA) for another 12 h.
Following stimulation, cells were washed and subsequently used
for phagocytosis assay.
In vitro Phagocytosis Assay
Phagocytosis assay was performed with M1 macrophages
generated as described above and assessed in triplicates by
incubation of cells with carboxylated, yellow-green fluorescent
FluoSpheresTM (F8823, Fisher Scientific, Germany) in serum-
free DMEM (with 1% Pen/Strep) in the presence of PACAP
(0.1, 1, and 10µM) for 4 h at 37◦C, 5% CO2. Negative
controls were established by keeping cells at 4◦C throughout
the experiment. After incubation, cells were washed twice with
PBS to remove remaining microspheres before detachment with
Accutase R© solution (423201, BioLegend). Finally, detached cells
were washed with PBS and directly stained with fluorochrome-
conjugated antibodies for flow cytometric analysis. In vitro
phagocytosis of microspheres was assessed by the median
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3 May 2019 | Volume 9 | Article 154
Figueiredo et al. Toxo Immune Modulation by PACAP
fluorescence intensity (MFI) of the positive population in the
FITC-fluorescence channel. Further, percentages of cells in the
FITC-positive fraction where divided according to the amount of
microspheres internalized.
DNA and RNA Isolation
DNA and RNA samples were isolated from peritoneal exudate
cells and spleens of acutely infected mice. Spleen samples
were homogenized in lysis buffer using BashingBeads Lysis
tubes (Zymo Research, Germany) and isolated using AllPrep
DNA/RNA Mini Kit (Qiagen, Germany) according to the
manufacturer’s instructions. For peritoneal exudate cells, parts
of the cell suspensions were pelleted down, resuspended in
lysis buffer and processed as describe above. The concentration
and purity of DNA and RNA samples was determined using
NanoDrop 2000 spectrophotometer (Thermo Fisher; Germany).
qPCR
Parasite burden was assessed in triplicates using 30 ng of isolated
DNA, FastStart Essential DNA Green Master and LightCycler R©
96 System (both Roche, Germany), as described previously
(Biswas et al., 2017). Thermal-cycling parameters were set as
follows: initial activation (95◦C, 10min), 45 amplification cycles
consisting of denaturation (95◦C, 15 s), annealing (60◦C, 15 s)
and elongation (72◦C, 15 s). The DNA target was the published
sequence of the highly conserved 35-fold-repetitive B1 gene
of T. gondii (Burg et al., 1989; Lin et al., 2000). Murine
argininosuccinate lyase (Asl) was used as reference gene for
normalization and relative DNA levels were determined by the
ratio gene of interest / reference gene and subsequently normalized
to mean values of control group (Butcher et al., 2011). Primers
were synthetized by Tib MolBiol (Germany) and used at 300 nM
final concentration.
RT-qPCR
Expression levels of cytokines, inflammatory mediators, host-
defense factors, neurotrophins, and neurotrophin receptors were
assessed in triplicates using 30 ng isolated RNA, TaqMan R©
RNA-to-CT
TM 1-Step Kit (Applied Biosystems, Germany) and
LightCycler R© 96 (Roche, Germany) as previously described
(Mohle et al., 2016). Thermal-cycling parameters were set as
follows: reverse transcription (48◦C, 15min), inactivation (95◦C,
10min) followed by 45 cycles of denaturation (95◦C, 15 s) and
annealing/extension (60◦C, 1min). Utilized TaqMan R© Gene
Expression Assays (Applied Biosystems, Germany) are listed in
Supplementary Table 1. Hprt was chosen as a reference gene
and relative mRNA levels were determined by the ratio gene
of interest/reference gene and subsequently normalized to mean
values of control group.
The expression of PACAP receptors were evaluated using
Power SYBR R© Green RNA-to-CTTM 1-Step Kit (Applied
Biosystems, Germany). Samples were analyzed in triplicates
(30 ng of isolated mRNA per reaction) using LightCycler R©
96 and the following parameters: reverse transcription (48◦C,
30min), inactivation (95◦C, 10min) followed by 55 cycles of
denaturation (95◦C, 15 s) and annealing/extension (60◦C, 1min)
and melting curve analysis. The primer sequences are listed in
Supplementary Table 1 and were synthetized by Tib MolBiol
and used at 100 nM final concentration. Expression of Hprt
was chosen as reference gene and relative mRNA levels were
determined by the ratio gene of interest / reference gene and
subsequently normalized to mean values of control group.
Statistical Analysis
Results were statistically analyzed using GraphPad Prism 7
(STATCON, Germany) and two-tailed unpaired t-test was used
on flow cytometry, qPCR and RT-qPCR data, and considered
significant for p ≤ 0.05. Statistical analysis of phagocytosis
assay data was carried out by applying one-way ANOVA with
post-hoc Holm-Sidak test. For plaque assay, data was analyzed
by one-way ANOVA followed by post-hoc Bonferroni test.
All data are presented as arithmetic mean ± standard error
of the mean (SEM) and are representative of two to three
independent experiments.
RESULTS
Immune Cell Recruitment Is Reduced
Following PACAP Administration
Upon acute infection with T. gondii, neutrophil granulocytes,
inflammatory monocytes and DCs are recruited to the site
of infection (Robben et al., 2005; Dunay et al., 2008; Dunay
and Sibley, 2010). To assess the effect of PACAP on cell
recruitment and activation upon acute infection, mice were
infected with tachyzoites, followed by administration of PACAP
or PBS (control). The peritoneal exudate cells were collected
and characterized by flow cytometry (Figure 1A). As our
previous studies demonstrated the critical importance of myeloid
cells in the control of T. gondii infection (Dunay et al.,
2010; Biswas et al., 2015; Mohle et al., 2016), we analyzed
the mononuclear compartment based on the expression of
CD11b and Ly6G. While the CD11b+Ly6G+ subset defined
neutrophil granulocytes, the fraction of CD11b+Ly6G− cells
was further discriminated into CD11chiMHCIIhi DCs as
previously described (Dupont et al., 2014). Subsequently,
remaining immune cells were then defined according to Ly6C
expression as Ly6Chi inflammatory monocytes and Ly6C−
peritoneal macrophages.
In general, the PACAP-treated group presented less recruited
cells in the peritoneal cavity (control: 1.67× 105 ± 0.10× 105 vs.
PACAP: 0.95× 105 ± 0.07× 105; p= 0.0012) (Figure 1B).When
compared to the controls, administration of PACAP significantly
reduced the recruitment of all analyzed myeloid cell subsets.
Ly6Chi inflammatorymonocytes appeared to be themost affected
cell population (control: 4.34× 104 ± 0.10× 103 vs. PACAP: 2.99
× 104 ± 2.41 × 103; p = 0.00003), followed by Ly6C− (control:
3.19 × 104 ± 2.75 × 103 vs. PACAP: 2.08 × 104 ± 2.15 × 103;
p = 0.0003) and neutrophils (control: 1.62 × 104 ± 2.09 × 103
vs. PACAP: 7.96 × 103 ± 7.7 × 102; p = 0.0043). No evident
difference was found for DCs (control: 4.02 × 103 ± 6.10 × 102
vs. PACAP: 1.92× 103 ± 2.29× 102; p= 0.4301) (Figure 1C). As
the ability to present antigens is dependent onMHCII expression,
we evaluated whether this was modulated by PACAP treatment
upon acute T. gondii infection. Our data indicated that PACAP
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FIGURE 1 | Immune cell recruitment and activation upon PACAP administration. Peritoneal cells of acutely-infected mice were analyzed by flow cytometry. Cells were
selected based on the forward-scatter/side-scatter plot (FSS/SSC) and living, single cells were chosen for further analysis (not shown). (A) Gating strategy used to
discriminate CD11b+Ly6G+ neutrophils and CD11b+Ly6G− monocyte-derived cells. CD11b+Ly6G− monocyte-derived cells were further divided into
CD11chiMHCIIhi DCs and then differentiated according to Ly6C expression: Ly6Chi inflammatory monocytes and Ly6C− peritoneal macrophages. (B) Shows the total
recruitment of living single cells. (C) Bar charts show cell recruitment of the identified cell populations in peritoneal cavity exudate of control and PACAP-treated groups
(control: black bars; PACAP-treated: white bars). (D) Histograms and bar charts show expression of the activation marker MHCII on peritoneal cell subsets according
to median fluorescence intensity (MFI). Control (black bars/histogram) and PACAP-treated (white bars/histogram); FMO (gray histogram) data are expressed as mean
± SEM, **p < 0.01, ***p < 0.001 (two-tailed unpaired t-test).
was able to increase the expression of MHCII on peritoneal DCs
(control: 2.74 × 105 ± 5.58 × 103 vs. PACAP: 3.06 × 105 ± 8.25
× 103; p = 0.0012) (Figure 1D) but not on the other myeloid
subsets (Ly6C−, control: 5.36 × 104 ± 3.23 × 103 vs. PACAP:
6.35× 104 ± 1.92× 103; p= 0.2448; Ly6Chi, control: 1.11× 105
± 4.91 × 103 vs. PACAP: 1.15 × 105 ± 8.21 × 103; p = 0.6767).
Thus, PACAP reduced the recruitment of mononuclear cells
to the peritoneal cavity upon T. gondii infection and increased
MHCII expression on peritoneal DCs.
Antiparasitic Effect of PACAP Is Immune
Cell-Mediated
Infected migratory immune cells, such as DCs, monocytes and
macrophages are responsible for the parasite dissemination
throughout host tissues, including lung, spleen, and also the
peritoneal cavity (Ueno et al., 2014). As previous reports
demonstrated the anti-parasitic effect of PACAP, we set out
to analyze whether PACAP administration is able to affect the
presence of T. gondii in myeloid-derived cell subsets. By infecting
mice with a GFP-fluorescent reporter parasite, we were able
to elucidate T. gondii occurrence in cell subsets isolated from
the peritoneal cavity via flow cytometry. Here, the experimental
group receiving PACAP showed a marked reduction of infected
cells in all myeloid populations (Figures 2A′–C′). Alongside with
Ly6G+ neutrophil granulocytes, Ly6Chi monocytes represented
the cell subset with the strongest reduction of parasitic GFP
signal, while DCs and Ly6C− macrophages were less affected
(neutrophils, control: 32 ± 5.6% vs. PACAP: 6.2 ± 0.34%;
p= 0.027; Ly6Chi, control: 26 ± 3% vs. PACAP: 5.5 ± 0.3%;
p= 0.0004; Ly6C−, control: 15 ± 1.5% vs. PACAP: 3.4 ± 0.19%;
p = 0.0003; DCs, control: 21 ± 2.5% vs. PACAP: 3.6 ± 0.65%;
p = 0.0006) (Figures 2A–C). In order to address if this was
mediated by the anti-parasitic effect of PACAP, we first performed
an in vitro plaque assay using HFF culture infected with T.
gondii in the presence of different PACAP concentrations (0.1,
1, and 10µM) (Figure 2D). In contrast to our in vivo data in
the peritoneal cavity, these results revealed that PACAP did not
directly affect the size (Figure 2D′) or the number of plaques
(Figure 2D′′). Thus, PACAP has no direct effect on parasite
elimination and/or impairment of the parasite development.
As infections with intracellular pathogens promote the
expression of host defense factors such as IRGs and GBPs
in myeloid cells, we hypothesized that these pathways were
modulated by PACAP possibly explaining the reduced parasite
burden in vivo. To this end, expression of IRGs (IRGM1,
IRGM3) and GBP2b on peritoneal cells isolated from acutely
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FIGURE 2 | Anti-parasitic effect of myeloid peritoneal immune cells upon PACAP-treatment. Peritoneal cells of acutely-infected mice were isolated and analyzed by
flow cytometry. A GFP-fluorescent T. gondii reporter was used to track the presence of the parasite in myeloid peritoneal subsets selected as described above. (A–C)
Contour plots show the presence of GFP+ cells for each cell subset in control (left column) and PACAP-treated (right column) group. Numbers represent the mean
percentage of parent population for each group from a representative experiment (n = 4). (A′–C′ ) Bar charts compare the frequency of GFP+ cells. Control (black
bars) and PACAP-treated (white bars). (D–D′′) Representative images show in vitro replication of T. gondii by plaque assays in the presence of PACAP. Plaques from
three independent experiments were scored for size and numbers using ImageJ. (D) Images of the formed plaques initially infected with 200 tachyzoites/well;
numbers indicate different PACAP concentration. (D′) Scored number of plaques under different concentrations of PACAP. (D′′) Scored plaque sizes shown as
arbitrary units (a.u.) in the presence of different PACAP concentrations. Data are expressed as mean ± SEM, **p < 0.01, ***p < 0.001 (two-tailed unpaired t-test).
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 6 May 2019 | Volume 9 | Article 154
Figueiredo et al. Toxo Immune Modulation by PACAP
infected mice was assessed by RT-qPCR (Figure 3A). Both
IRGs were upregulated in the group that received PACAP
(IRGM1: p = 0.0329; IRGM3: p = 0.0220), suggesting that the
observed decrease in parasite burden might be associated with
an improved phagocytic ability, also reported to be modulated
by PACAP (Delgado et al., 1996a). Therefore, we performed,
a phagocytosis assay with bone marrow-derived macrophages
(BMDMs) primed to a classically activated M1 phenotype and
stimulated with different concentrations of PACAP (Figure 3B).
When compared to the non-treated group all PACAP-treated
groups showed an increased phagocytosis as displayed by the
MFI, with the highest effect observed at 1µM concentration
(control vs. 0.1µM PACAP: p < 0.0001; control vs. 1µM
PACAP: p < 0.0001; control vs. 10µM PACAP: p < 0.0001).
With the signal of FITC-fluorescent microspheres being well
distinguishable by flow cytometry, we were further able to
subdivide the composition of each experimental group based on
the number of beads being phagocyted (Figure 3B′). In line with
the MFI data, all PACAP-treated groups showed an increased
number of internalized microspheres when compared to the
non-treated control. Moreover, treatment with 1µM PACAP
resulted in the largest fraction of BMDMs with more than 3
beads engulfed when compared to other groups (control: 68.3
± 1.007 %; 0.1µM PACAP: 79.33 ± 0.9939; 1µM PACAP: 88.9
± 1.0044 %; 10µM PACAP: 81.3 ± 0 %). These findings were
further supported by analysis of BMDMs with respect to their
expression of the macrophage marker F4/80 (Figure 3C). Also
here, PACAP treatment resulted in upregulation of F4/80 that
was most prominent in the group treated with 1µM PACAP
(control vs. 0.1µMPACAP: p< 0.0045; control vs. 1µMPACAP:
p < 0.0004; control vs. 10µM PACAP: p < 0.004). Altogether,
these results demonstrate that the neuropeptide PACAP was
able to reduce the presence of T. gondii in peritoneal myeloid
cells not by a direct anti-parasitic effect but by modulating their
phagocytic capabilities.
Decreased Parasite Burden and
Expression of Inflammatory Mediators
Previous studies have shown that PACAP inhibits the production
of pro-inflammatory cytokines (Martinez et al., 1998a; Delgado
et al., 1999a,b). In order to evaluate how PACAP affects the
acute inflammation caused by T. gondii, we assessed the parasite
burden and the gene expression of inflammatory mediators
(Figure 4). The results show a reduced parasite load (p =
0.0171) in the PACAP-treated group and reduced expression
of IFN-γ (p = 0.0022), TNF (p = 0.0069), IL-6 (p = 0.0009),
CCL-2 (p= 0.0009), and iNOS (p = 0.0451). Expression levels
of IL-12, IFN-β, IL-10, and TGF-β did not differ between
PACAP and the control group. In summary, PACAP was able
to reduce parasite burden while diminishing the robust Th1
response characteristic for T. gondii infection without affecting
anti-inflammatory mediators.
Immune Cells Upregulate PACAP
Receptors and Neurotrophin Expression
PACAP-mediated effects on immune cells are elicited by binding
of the neuropeptide to its receptors PAC1, VPAC1, and VPAC2,
whereby the main anti-inflammatory effect is primarily exerted
through VPAC1 resulting in activation of the cAMP/PKA
pathway (Delgado et al., 2004a). This signaling pathway regulates
the activity of a range of transcription factors critical for
expression of the most inflammatory mediators (Delgado et al.,
1998, 1999a; Delgado and Ganea, 1999, 2001). Therefore, we
evaluated whether PACAP modulates the expression of its
intrinsic receptors on peritoneal immune cells upon T. gondii
infection (Figure 5A). Our results show that the neuropeptide
was able to increase the expression of VPAC1 and VPAC2 ∼3
fold when compared to the control group (VPAC1: p = 0.00001;
VPAC2: p= 0.035). Thus, while PACAP binds to its own receptor,
it also regulates their expression on innate immune cells.
Previous studies have shown the involvement of VPAC1
in myeloid cells and the PACAP-mediated signal transduction
into neurotrophin signaling (El Zein et al., 2007). In general,
neurotrophins are associated with the growth, development and
survival of neuronal cells in the CNS (Mitre et al., 2017).
However, besides neuronal tissue, neurotrophin receptors of the
Trk superfamily and the p75 neurotrophin receptor (p75NTR)
were detected in a variety of immune cells (Frossard et al., 2004;
Fischer et al., 2008; Minnone et al., 2017), thus emphasizing
the interdependency of the neuronal and immune system.
In accordance with that, our previous work indicates that
neurotrophin signaling via the p75NTR affects innate immune cell
behavior upon T. gondii-induced neuroinflammation (Dusedau
et al., 2019). Therefore, to further explore the influence
of PACAP-mediated signaling on the neurotrophin signaling
pathway as another modulator of the innate immune response,
we analyzed the expression of BDNF and neurotrophin receptors
(p75NTR, TrkA, TrkB, and TrkC) in peritoneal exudate cells upon
acute infection (Figure 5B). Surprisingly, BDNF expression level
was found to be elevated ∼6 fold in PACAP-treated animals
when compared to the control group (BDNF, p = 0.0129;
p75NTR, p = 0.0584; TrkA, p = 0.9990; TrkB, p = 0.9992; TrkC,
p= 0.9674). Altogether, our results indicate an upregulation
of BDNF expression upon PACAP treatment, suggesting a
modulation of neurotrophin pathways in innate immune cells
upon acute T. gondii infection.
PACAP Reduce p75NTR Expression on
Ly6Chi Monocytes
We have recently highlighted the upregulation of p75NTR on
innate immune cells in the blood and brain of infected animals
in T. gondii-induced neuroinflammation (Dusedau et al., 2019).
In the periphery, the infection increased p75NTR expression
on myeloid cell subsets, which are essential for control of
toxoplasmosis (Dunay et al., 2010; Biswas et al., 2015). To this
end, we analyzed expression of p75NTR on Ly6Chi inflammatory
monocytes and Ly6C− resident macrophages isolated from
the peritoneal cavity upon acute infection. In the PACAP-
treated group, the p75NTR expression on Ly6Chi monocytes was
significantly reduced (Ly6Chi, p < 0.00001; Ly6C−, p = 0.29)
(Figure 5C) with no changes in frequency of p75NTR+ cells for
Ly6Chi (p = 0.276) or Ly6C− (p = 0.5181) (Figure 5D). Taken
together, our results point toward the anti-inflammatory effect of
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FIGURE 3 | PACAP treatment increases expression of host-defense factors and phagocytosis. (A) Bar charts show gene expression of IRGs and GBP2b associated
with parasite elimination in peritoneal exudate cells assessed by RT-qPCR. The gene expression levels of host defense factors were determined by RT-qPCR using
Hprt as reference gene. Data were further normalized to mean values of control group; Control (black bars) and PACAP-treated (white bars). Bar charts present results
as mean ± SEM, n = 4; *p < 0.05 (two-tailed unpaired t-test). (B) Phagocytosis of BMDMs primed to M1 phenotype was assessed by incubation with
FITC-fluorescent microspheres in the presence of different PACAP concentrations (0.1, 1, and 10µM); phagocytic capability was evaluated by the MFI of the positive
populations. (B’) Histograms and bar charts show frequency cells fractioned according to the amount of microspheres internalized. (C) Histograms and bar charts
show activation marker F4/80 expressed on BMDMS in the phagocytosis assay. Data are expressed as mean ± SEM (one-way ANOVA with post-hoc
Holm-Sidak test).
PACAP on Ly6Chi monocytes, and suggest the involvement of
p75NTR in the acute inflammatory response against T. gondii.
DISCUSSION
We hypothesized that application of the neuropeptide PACAP
might modulate the behavior of myeloid-derived mononuclear
cells and potentially contribute to the resolution of the infection
and parasite elimination. Accordingly, we investigated the
immunomodulatory effect of PACAP on innate immune cells
isolated from the peritoneal cavity during experimental acute
T. gondii infection. We detected an interaction of PACAP
and neurotrophin signaling that suggests a contribution to the
resolution of acute Toxoplasmosis.
Previously, we have reported that PACAP administration
ameliorates acute small intestinal inflammation and extra-
intestinal sequelae during acute ileitis caused by T. gondii
infection (Heimesaat et al., 2014; Bereswill et al., 2019).
Besides, we demonstrated the critical importance of myeloid
cells to control T. gondii infection in the periphery as well
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 8 May 2019 | Volume 9 | Article 154
Figueiredo et al. Toxo Immune Modulation by PACAP
FIGURE 4 | PACAP alters parasite burden and inflammatory mediators. DNA and RNA were isolated from spleens of acutely infected mice and analyzed by qPCR
and RT-qPCR. The parasite burden was determined based on the presence of B1 gene of T. gondii (TgB1) normalized to the murine gene Asl. The gene expression
levels of inflammatory mediators were determined by RT-qPCR using Hprt as reference gene. Data were further normalized to mean values of control group; Control
(black bars) and PACAP-treated (white bars). Bar charts present results as mean ± SEM, n = 4. *p < 0.05, **p < 0.01, ***p < 0.001 (two-tailed unpaired t-test).
as in the CNS (Dunay et al., 2008, 2010; Biswas et al.,
2015; Mohle et al., 2016). Furthermore, our recent studies
have revealed the emerging role of neurotrophin signaling
via p75NTR that affects innate immune cell behavior and
influences structural plasticity of neurons upon T. gondii-
induced neuroinflammation (Dusedau et al., 2019). Therefore, we
analyzed the effects of PACAP on the course of acute T. gondii
infection in mice.
Initially, our data revealed that in the peritoneal cavity,
the number of recruited myeloid cells, especially Ly6Chi
inflammatory monocytes, was reduced by the administration
of exogenous PACAP. PACAP has been shown to modulate
chemokines produced by activated macrophages and adhesion
molecules expressed by granulocytes, thereby affecting the
recruitment of different immune cell subsets (Ganea and
Delgado, 2002; El Zein et al., 2008). Under steady-state
conditions, two types of macrophages are found in the peritoneal
cavity: large peritoneal macrophages (LPMs) and small peritoneal
macrophages (SPMs) (Ghosn et al., 2010). During inflammation,
the peritoneal cell composition dramatically changes, with
a massive recruitment of Ly6Chi monocytes that give rise
to new SPMs, while LPMs leave the peritoneal cavity and
migrate to the omentum for antigen presentation (Cassado
Ados et al., 2015). Upon in vitro LPS stimulation, SPMs
developed a pro-inflammatory profile as indicated by TNF,
CCL3 and RANTES production (Cain et al., 2013). These
findings align with our previous results where Ly6Chi monocytes
contributed to T. gondii removal via production of TNF, iNOS
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FIGURE 5 | Expression of PACAP receptors, BDNF and neurotrophin receptors on peritoneal cells. Gene expression of (A) PACAP receptors and (B) BDNF and
neurotrophin receptors was assessed by RT-qPCR. Control (black bars) and PACAP-treated (white bars); data are expressed as mean ± SEM, *p < 0.05, ***p <
0.001 (two-tailed unpaired t-test). (C) Flow cytometric analysis of p75NTR expression on immune cell subsets; the histograms show the FMO control (light gray-tinted),
control group (black-tinted) and PACAP group (black non-tinted); bar charts present the values of MFI for p75NTR expression. (D) Frequency of cells from parent
population of living, single p75NTR+ cells. Data are presented as mean ± SEM, n = 4. ****p < 0.0001 (two-tailed unpaired t-test).
and reactive oxygen species (ROS) (Dunay et al., 2008, 2010;
Dunay and Sibley, 2010; Karlmark et al., 2012). Analyzing
the gene expression of selected chemokines, cytokines and
inflammatory mediators, we detected that exposure to PACAP
diminished the levels of TNF, IL-6, and iNOS similarly to
our previous observations in the intestine (Heimesaat et al.,
2014). Moreover, the expression of the chemokine CCL2,
important for the recruitment of Ly6Chi monocytes (Biswas et al.,
2015), was also significantly downregulated further supporting
our observations of reduced myeloid cell recruitment. Levels
of the anti-inflammatory cytokine IL-10 were not elevated,
but remained balanced upon PACAP administration in our
experimental setup. These data are in line with a previous finding
in a study with experimental autoimmune encephalomyelitis
(EAE), where PACAP was able to reduce IFN-γ levels but had
no effect on production of IL-10 by spleenocytes (Kato et al.,
2004).
Interestingly, we observed a decreased systemic parasite
burden despite IFN-γ being negatively affected by the
administration of PACAP. Generally, downregulation of
IFN-γ, the main driving force against T. gondii infection,
would result in an uncontrolled parasite replication (Suzuki
et al., 1988). Contrary to previous reports with Trypanosoma
(Delgado et al., 2009), we did not detect direct antiparasitic
effects of PACAP on the T. gondii replication, which was
assessed by monitoring changes in the size or the number of
plaques. Instead, IFN-β was found to be upregulated by tendency
after exposure to PACAP. The expression of the inflammatory
cytokine IFN-β is upregulated following T. gondii infection
(Mahmoud et al., 2015). Anti-parasitic effects of type I IFNs in
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myeloid cells are independent from iNOS and IFN-γ-induced
effects. IFN-β acts via induction of IRGM1 that accumulates
on the parasitophorous vacuole (PV), in order to disrupt it
(Mahmoud et al., 2015). Therefore, we further analyzed the
expression of IRGs (IRGM1, IRGM3, GBP2b) and other host
defense factors associated with PV disruption. Here, we observed
upregulated expression of IRGM1/IRGM3, which implies that
PACAP modulates immune cell-mediated parasite elimination
rather than direct anti-parasitic effects. Our results align with
previous studies (Delgado et al., 1996a), where macrophages
exhibit an increased F4/80 expression and enhanced
phagocytic capacity.
In contrast to Ly6Chi monocytes and Ly6G+ neutrophils,
CD11c+ DC recruitment was not affected by PACAP. However,
the expression of MHCII in the PACAP-treated group was
increased, pointing toward a promotion of antigen recognition
and subsequent activation of lymphocytes. In line with previous
studies, PACAP-mediated effects on DCs have shown to be
mainly induced by signaling through VPAC1, which is the same
receptor-mediated pathway utilized for macrophages (Delgado
et al., 2004b). Indeed, PACAP administration upregulated the
expression of VPAC1 and VPAC2 but not PAC1 by peritoneal
exudate cells from acutely infectedmice. All three receptors result
in the activation of cyclic adenosinemonophosphate (cAMP) and
the subsequent activation of protein kinase A (PKA) (Delgado
et al., 2004a). Specific studies using agonists and antagonists for
PACAP receptors have established VPAC1 as the major mediator
of the immunomodulatory effects from PACAP, both in vitro
and in vivo, with moderate involvement of VPAC2, and minimal
or none from PAC1 (Delgado et al., 2004a). Interestingly, in
human neutrophils and monocytes, PACAP interaction with
VPAC1 and the NGF receptor TrkA resulted in calcium
mobilization and subsequent pro-inflammatory activation (El
Zein et al., 2006, 2007). Even though PACAP exposure had
no effect on the gene expression of Trk receptors, we detected
an upregulation of BDNF expression by immune cells upon
PACAP administration.
It was previously reported that PACAP upregulated BDNF
expression in primary neuronal cultures from rat cerebral cortex,
as well as in human neuroblastoma cells upon injury (Frechilla
et al., 2001; Shintani et al., 2005; Brown et al., 2013). BDNF
is able to influence the immune system via modulation of
cytokine expression in peripheral blood mononuclear cells (Vega
et al., 2003). BDNF was shown to also be produced by immune
cells (Kruse et al., 2007), to modulate monocyte chemotaxis,
participate in tissue-healing mechanisms (Samah et al., 2008),
and enhance macrophage phagocytic activity (Hashimoto
et al., 2005). Recently, we have described a specific role of
neurotrophins and their receptors during neuroinflammation.
We described that the BDNF receptor p75NTR has a functional
impact on the activation status of innate immune cells during
T. gondii-induced neuroinflammation (Dusedau et al., 2019).
Here, PACAP was able to reduce the overall recruitment
of myeloid-derived mononuclear cells to the peritoneal
cavity; in particular, Ly6Chi monocytes. Interestingly, the
same cell subset presented higher p75NTR expression than
Ly6C− peritoneal macrophages, and the administration of
PACAP exclusively reduced p75NTR expression on Ly6Chi
monocytes. In previous studies (Lee et al., 2016), the use of
an antagonist blocker of p75NTR reduced the recruitment
of inflammatory monocytes to the CNS, further suggesting
that neurotrophin signaling is involved in immune cell
migration. Moreover, in a model of in EAE model, the
induction of the inflammation resulted in expression of
p75NTR in endothelial cells. Although they focus on endothelial
p75NTR expression, the study reports a differential immune
cell recruitment to the CNS of p75NTR knockout mice, with
reduced numbers of cells from the monocyte-macrophage
lineage (Kust et al., 2006). In other studies, p75NTR expression
by immune cells was reported to increase by a factor of
10 in response to injury (Ralainirina et al., 2010). Our
previous work also showed p75NTR upregulation on resident
microglia cells and myeloid-derived mononuclear cell subsets
in T. gondii-infected brains (Dusedau et al., 2019). These studies
supported our findings, where immune cell recruitment and the
expression of p75NTR upon inflammation were reduced upon
PACAP treatment.
Alongside BDNF, p75NTR signaling in immune cells can
be modulated by levels of neurotrophin precursors (pro-
neurotrophins). proBDNF has been shown to negatively affect
neuronal plasticity and cell death, reinforced by elevated levels
of proBDNF detected in peripheral macrophages (Wong et al.,
2010; Luo et al., 2016; Dusedau et al., 2019). Here we observed
a downregulation of p75NTR, implying a reduced influence
of pro-neurotrophins on Ly6Chi monocytes and thus having
a beneficial effect on the resolution of inflammation. The
increase of BDNF gene expression in response to PACAP
treatment and the involvement of neurotrophins/receptors with
VPAC1, especially on neutrophils and monocytes, suggest a
possible interaction between p75NTR, BDNF and PACAP within
myeloid cells during an inflammatory response. However, future
experiments should investigate whether the downregulation of
p75NTR is directly PACAP-mediated or a result of an overall
reduced inflammation.
In our experiments, the effect of PACAP on parasite
elimination may correlate with the synergic, indirect effect
of elevated BDNF expression by peritoneal immune cells.
However, the role of p75NTR signaling in relation to the
immune system remains poorly understood due to the
complex interplay of mature vs. pro-neurotrophins, and
heterodimeric interactions with Trk receptors (Meeker and
Williams, 2014). In summary, our results indicate different
routes of PACAP-mediated regulation of the innate response
during acute T. gondii infection. As a potent immunomodulator,
PACAP has been shown to contribute to the resolution
of acute inflammation and parasite elimination by innate
immune cells. Furthermore, our findings point toward a
potential connection between PACAP and neurotrophin-
mediated signaling in Ly6Chi inflammatory monocytes. Taken
together, these results contribute to the understanding of
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the interaction between the nervous and immune systems
through neuropeptides.
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